A new portable device that utilizes artificial intelligence (AI) and biosensors can rapidly detect if cancer cells thrive after chemotherapy treatment. A team of researchers at Rutgers University has designed a new portable device that is up to 95.9 percent effective and accurate in counting living cancer cells when they pass through certain electrodes. This way, doctors can see if the targeted chemotherapy treatment was effective. Published in the journal Microsystems & Nanoengineering, the study aims to devise a new and simple method to rapidly assess drug efficacy in targeted chemotherapy cancer therapy, where anticancer drugs are conjugated to antibodies that target surface markers on cancer cells. Cancer continues to be one of the leading causes of mortality and death across the globe.

Monsoon CreditTech has become one of the seven fintech companies from across the world and the only one from India selected by Mastercard Start Path, part of Mastercard Labs, to be part of its startup engagement program. Start Path is designed to help later stage startups scale their business. This puts Monsoon in an elite club of companies and will give Monsoon access to Mastercard's global network of customers and subject matter experts, bringing Monsoon's machine learning technology to global markets outside India. Monsoon says it has also recently closed a new round of undisclosed amount in funding from strategic institutional and individual investors from across the globe ranging from geographies such as USA, UK, UAE and India. The digital shift As the volume of data available for analysis grows and computational power becomes cheaper, banks and financial institutions are beginning to realize the potentially transformational benefits of embracing Artificial Intelligence (of which machine learning is a subset).

Elon Musk, the futurist billionaire behind SpaceX and Tesla, outlined his plans to connect humans' brains directly to computers on Tuesday night, describing a campaign to create "symbiosis with artificial intelligence." He said the first prototype could be implanted in a person by the end of next year. Arriving at that goal "will take a long time," Musk said in a presentation at the California Academy of Sciences in San Francisco, noting that securing federal approval for implanted neural devices is difficult. But testing on animals is already underway, and "a monkey has been able to control the computer with his brain," he said. Musk founded Neuralink Corp. in July 2016 to create "ultra-high bandwidth brain-machine interfaces to connect humans and computers."

To gain broad insight into the AI and ML landscape beyond the market hype. To gain high level understanding of the architectures, algorithms, platforms, APIs, and libraries for AI/ML development, current and future AI/ML application domains, and domain-specific models and algorithms. To gain pragmatic understanding of career prospects and emerging opportunities in AI/ML and how to prepare for them. To gain broad insight into the AI and ML landscape beyond the market hype. To gain high level understanding of the architectures, algorithms, platforms, APIs, and libraries for AI/ML development, current and future AI/ML application domains, and domain-specific models and algorithms.

Researchers have developed an AI algorithm which can solve a Rubik's cube in a fraction of a second, according to a study published in the journal Nature Machine Intelligence. The system, known as DeepCubeA, uses a form of machine learning which teaches itself how to play in order to crack the puzzle without being specifically coached by humans. "Artificial intelligence can defeat the world's best human chess and Go players, but some of the more difficult puzzles, such as the Rubik's Cube, had not been solved by computers, so we thought they were open for AI approaches," Pierre Baldi, one of the developers of the algorithm and computer scientist from the University of California, Irvine, said in a statement. According to Baldi, the latest development could herald a new generation of artificial intelligence (AI) deep-learning systems which are more advanced than those used in commercially available applications such as Siri and Alexa. "These systems are not really intelligent; they're brittle, and you can easily break or fool them," Baldi said.

In a statement, CLDC says that it will work with Rui Xin to develop a consumer financial platform. CLDC expects to provide value-added consumer financial services to insurance consumers of Rui Xin and its partners. In addition, CLDC and Rui Xin will explore opportunities for collaboration in areas such as insurance consumer acquisition, development of insurance products, expansion of insurance business, and customisation of consumer financial solutions. Moreover, CLDC will benefit from Rui Xin and its partners' advanced technological capabilities in big data and artificial intelligence to improve its risk management and enhance its customer experience. In its turn, Rui Xin will be able to explore new business opportunities and increase its competency to eventually expand its customer base in the insurance industry by benefiting from CLDC's financial service expertise, bank credit facility resources, and client base in certain regional markets.

In the not-so-distant past, the gatekeepers to publishing were large publishing houses. They guarded this right jealously, and self-publishing books was looked upon with disdain. These days, it is often impossible to distinguish high-quality self-published books from those that received traditional backing. As Forbes notes, self-published writers are now becoming tiny publishing houses of their own by outsourcing the talent they need to make their books a success. Artificial intelligence has only helped to make the whole process easier.

What if technology could predict a hereditary disease you could stop from progressing? What if a visit to your primary physician for carpal tunnel syndrome ended with a suggestion to get tested for a rare illness? As Komodo Health's artificial intelligence algorithms crunch a decade of data about health conditions across several hundred million Americans, many what-if scenarios are becoming pathways for the next clinical assessment to be taken. Founded in 2014, Komodo, funded by Felicis Ventures and McKesson Ventures, has mapped out 300 million individual health identities across the country to find patterns signaling the presence of disease, years before they're ever diagnosed. At a time when chronic conditions account for 75 percent of the $3 trillion US healthcare spend annually, identifying when symptoms occur earliest or recognizing patterns of activity that are often a precursor to the manifestation of diseases is vital in preventing those economically, physically and mentally crippling illnesses to either exist or progress.

On July 15, 2019 Paige, the leader in computational pathology focused on building artificial intelligence (AI) to transform the clinical diagnosis and treatment of cancer, reported the publication of an article in Nature Medicine, a leading monthly journal publishing original peer-reviewed research in all areas of medicine, describing an AI system for computational pathology that achieves clinical-grade accuracy levels (Press release, Paige AI, JUL 15, 2019, View Source [SID1234537535]). The paper provides further scientific evidence that pathologists' work in diagnosing and treating cancer can be complemented and aided through the deployment of computational decision-support systems to improve patient care. NEW REPORT: Immuno-Oncology Drug Development: Analytical Tool Immuno-Oncology Drug Development: Analytical Tool is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot and fast moving area in oncology. This unique product is truly the only one of its kind and is designed to give you a competitive edge in your I-O drug intelligence. Covers more than 1204 companies plus partners who are today developing 3691 I-O drugs in cancer across 617 different targets.

The first drug developed by artificial intelligence is a vaccine for the flu. Smart Algorithms for Medical Discovery (SAM) was given information about compounds that help the immune system along with those that don't. From this input, SAM created a flu vaccine that has so far proven effective in animals.